Home Cart Sign in  
Chemical Structure| 1617495-03-0 Chemical Structure| 1617495-03-0

Structure of RA190
CAS No.: 1617495-03-0

Chemical Structure| 1617495-03-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

RA190 is a potent Rpn13 inhibitor and ADRM1 Inhibitor, Suppressing Intrahepatic Cholangiocarcinoma by Inducing NF-kappaB-Mediated Cell Apoptosis. RA190 represents a novel class of proteasome inhibitor that covalently binds to cysteine 88 of RPN13, an ubiquitin receptor subunit of the proteasome's 19S regulatory particle. RA190 treatment inhibits proteasome function, causing rapid accumulation of polyubiquitinated proteins. RA190 has therapeutic activity in a xenograft model, and with sorafenib exhibited synergetic killing of HCC cells in vitro, suggesting further exploration of such a combination treatment of HCC is warranted.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of RA190

CAS No. :1617495-03-0
Formula : C28H23Cl5N2O2
M.W : 596.76
SMILES Code : O=C1/C(CN(C([C@H](CC2=CC=CC=C2)N)=O)C/C1=C/C3=CC=C(Cl)C(Cl)=C3)=C\C4=CC=C(Cl)C(Cl)=C4.[H]Cl
MDL No. :MFCD30738021
InChI Key :UMWXLEVUBFNYIK-VCCJZKHWSA-N
Pubchem ID :126843229

Safety of RA190

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MM.1S cells 0.5 µM 6 hours RA190 treatment elevated Bax protein levels Cancer Cell. 2013 Dec 9;24(6):791-805
SK-MEL-5 cells 30 µM 1 hour To assess the alkylation activity of RA190 in cell lysates, results showed that RA190 can alkylate multiple proteins, exhibiting broad alkylation activity. Cell Chem Biol. 2020 Nov 19;27(11):1371-1382. e6
HeLa cells 1 µM 1 hour To assess the alkylation of Rpn13 by RA190, results showed that RA190 can alkylate Rpn13 but not selectively at the C88 site. Cell Chem Biol. 2020 Nov 19;27(11):1371-1382. e6
MM.1S cells 300 nM 12 hours RA190 triggered caspase-3, caspase-8, and caspase-9-mediated apoptotic signaling cascades. Leukemia. 2016 Sep;30(9):1877-86
ANBL6.BR cells 300 nM 12 hours RA190 decreased expression of G2/M-phase cell-cycle regulatory proteins CDC25C, CDC2, and cyclin B1. Leukemia. 2016 Sep;30(9):1877-86
HepG2 1 µM or 2 µM 12 hours To evaluate the effect of RA190 on the levels of polyubiquitinated proteins in HepG2 cells, the results showed that RA190 treatment significantly increased the levels of polyubiquitinated proteins in a dose-dependent manner. BMC Cancer. 2020 May 6;20(1):386
HeLa cells 1 µM 12 hours RA190 treatment leads to a block in DNA replication and cell cycle arrest in G2, and induces apoptosis. J Biol Chem. 2016 Apr 15;291(16):8773-83
ANBL6.BR cells 500 nM 16 hours To evaluate the effect of WL40 in bortezomib-resistant cells. Results showed that WL40 induced RPN13 degradation. Leukemia. 2019 Nov;33(11):2685-2694
RPMI-8226 cells 500 nM 16 hours To evaluate the effect of WL40 in p53-mutated cells. Results showed that WL40 induced RPN13 degradation. Leukemia. 2019 Nov;33(11):2685-2694
CRBN-knockout MM.1S cells 500 nM 16 hours To confirm the requirement of CRBN for WL40 function. Results showed that WL40 did not decrease Rpn13 levels in CRBN-KO cells. Leukemia. 2019 Nov;33(11):2685-2694
MM.1S cells 500 nM 16 hours To analyze intracellular alterations in Rpn13 using flow cytometry. Results showed that WL40 treatment significantly reduced Rpn13 expression. Leukemia. 2019 Nov;33(11):2685-2694
HCT116 ΔUCHL5 1 µM 24 hours Evaluate the effect of RA190 on ubiquitinated protein accumulation, showing RA190 treatment caused accumulation in ΔUCHL5 cells Mol Cell Biol. 2020 Aug 28;40(18):e00122-20
HCT116 1 µM 24 hours Evaluate the effect of RA190 on ubiquitinated protein accumulation, showing RA190 treatment caused accumulation in WT cells but was attenuated in trRpn13 cells Mol Cell Biol. 2020 Aug 28;40(18):e00122-20
MM.1S cells 300 nM 24 hours RA190 significantly increased both early and late apoptotic cell populations, as assessed by Annexin V/PI double staining. Leukemia. 2016 Sep;30(9):1877-86
MM.1S cells 300 nM 24 hours RA190 induced significant G2/M-phase growth arrest, with a concomitant increase in the S phase, and decreased expression of G2/M-phase cell-cycle regulatory proteins CDC25C, CDC2, and cyclin B1. Leukemia. 2016 Sep;30(9):1877-86
U266 >10 µM 24 hours To evaluate the antiproliferative effects of RA190 on multiple myeloma cell lines Front Immunol. 2023 Mar 2;14:982720
OPM-2 >10 µM 24 hours To evaluate the antiproliferative effects of RA190 on multiple myeloma cell lines Front Immunol. 2023 Mar 2;14:982720
KMS12BM >10 µM 24 hours To evaluate the antiproliferative effects of RA190 on multiple myeloma cell lines Front Immunol. 2023 Mar 2;14:982720
NCI-H929 >10 µM 24 hours To evaluate the antiproliferative effects of RA190 on multiple myeloma cell lines Front Immunol. 2023 Mar 2;14:982720
MM1S >10 µM 24 hours To evaluate the antiproliferative effects of RA190 on multiple myeloma cell lines Front Immunol. 2023 Mar 2;14:982720
RPMI-R5 >10 µM 24 hours To evaluate the antiproliferative effects of RA190 on multiple myeloma cell lines Front Immunol. 2023 Mar 2;14:982720
RPMI-8226 >10 µM 24 hours To evaluate the antiproliferative effects of RA190 on multiple myeloma cell lines Front Immunol. 2023 Mar 2;14:982720
ANBL6-WT and ANBL6-BR cells 1.25 µM 24 hours RA190 showed anti-MM activity in both bortezomib-sensitive and -resistant cells and reduced SOD1 levels Leukemia. 2021 Feb;35(2):550-561
MM.1S cells 0.25 µM 24 hours RA190 significantly downregulated SOD1 expression (2.6-fold decrease) and triggered cytotoxicity Leukemia. 2021 Feb;35(2):550-561
CaSki cells 1 µM 4 hours RA190 treatment caused accumulation of K48-linked polyubiquitinated proteins Cancer Cell. 2013 Dec 9;24(6):791-805
HeLa cells 1 µM 4 hours RA190 treatment caused accumulation of K48-linked polyubiquitinated proteins Cancer Cell. 2013 Dec 9;24(6):791-805
Ovarian cancer cell lines 1.2–2.3 µM (IC50) 48 hours Evaluate sensitivity of RA190 across ovarian cancer cell lines, all lines were sensitive to RA190 J Ovarian Res. 2017 Aug 7;10(1):53
HepG2 0.15 µM 72 hours To evaluate the cytotoxic effect of RA190 on HepG2 cells, the results showed that the IC50 of RA190 was 0.15 μM, significantly lower than that of sorafenib (9.7 μM). BMC Cancer. 2020 May 6;20(1):386

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
CB-17 SCID mice Human plasmacytoma MM.1S xenograft model Intraperitoneal injection 15 mg/kg Two times weekly for 18 days RA190 inhibited MM tumor growth and prolonged survival of mice, with good tolerability. Tumor analysis showed increased PARP cleavage, caspase-7 activation, and polyubiquitylation. Leukemia. 2016 Sep;30(9):1877-86
Mice NOG mice carrying NCI-H929-GFP-luc human tumor cells Intraperitoneal injection 20 mg/kg Once per day for 7 days RA190 significantly inhibited tumor growth Cancer Cell. 2013 Dec 9;24(6):791-805
Nude mice Orthotopic HCC xenograft model Intraperitoneal injection 20 mg/kg Once daily for 21 days To evaluate the therapeutic effect of RA190 in an orthotopic HCC xenograft model, the results showed that RA190 significantly reduced tumor growth. BMC Cancer. 2020 May 6;20(1):386

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.68mL

0.34mL

0.17mL

8.38mL

1.68mL

0.84mL

16.76mL

3.35mL

1.68mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories